Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
(BOSS Trial)
Recruiting at 2 trial locations
CT
Overseen ByClinical Trials Referral Office
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Mayo Clinic
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease
Research Team
RO
Roman O. Kowalchuk, MD
Principal Investigator
Mayo Clinic in Rochester
Eligibility Criteria
Inclusion Criteria
You have provided written, informed consent.
You are at least 18 years of age.
You have been diagnosed with primary breast cancer through histological examination.
See 7 more
Treatment Details
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Metastatic Breast CancerExperimental Treatment6 Interventions
Breast cancer patients with ER+/PR± (any PR status)/HER2- disease or HER2+ disease (any ER or PR status) will receive radiotherapy that consists primarily of Stereotactic body radiation therapy (SBRT), but at a minimum, it will consist of dose-escalated, moderately hypofractionated radiotherapy (as opposed to conventional fractionation or conventional palliative treatment regimens).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Trials
3,427
Recruited
3,221,000+
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.